This study investigates colorectal and pancreatic cancer with KRAS mutations. The purpose is to use a vaccine made from a special type of bacteria to help patients after surgery.
The study evaluates the safety and how well the vaccine works in the body. It looks at how the body reacts and if the vaccine helps protect against cancer returning.
- Who can participate: Adults aged 18 to 75 with colorectal or pancreatic cancer, specific KRAS mutations, and who have completed surgery and chemotherapy may join.
- Study details: Participants will receive a vaccine made from a special bacteria. Some will also receive another medicine to evaluate their combined effects. A placebo is an inactive substance that looks like the investigational medicine but does not contain any medicine.
- Study visits: The study requires 9 visits.
How understandable was the trial content above?
Hard to understand
Easy to understand